Skip to main content

Table 4 Incidence of adverse drug reactions

From: Effectiveness of medical supportive team for outpatients treated with sorafenib: a retrospective study

Adverse drug reactions Intervention group (n = 31) n (%) Non-intervention group (n = 39) n (%) P-value (Any)
Grade Any 3 ~ 4 Any 3 ~ 4  
Hand-foot skin reactiona 23(74.2) 2(6.5) 19(48.7) 3(7.7) 0.049*
Diarrhea 21(67.7) 2(6.5) 5(12.8) 1(2.6) < 0.001**
Hypertension 16(51.6) 6(19.4) 15(38.5) 5(12.5) 0.336
Anorexia 15(48.4) 1(3.2) 6(15.4) - 0.002**
Hair loss 13(41.9) - 5(12.8) - 0.012*
Thrombocytopenia 11(35.5) 2(6.5) 4(10.3) 3(7.7) 0.018*
AST increased 11(35.5) 5(16.1) 6(15.4) 3(7.7) 0.091
Hoarseness 10(32.3) - 4(10.3) - 0.034*
ALT increased 9(29.0) - 6(15.4) 3(7.7) 0.242
Serum amylase increased 9(29.0) 6(19.4) 3(7.7) 1(2.6) 0.026*
Fatigue 7(22.6) - 1(2.6) - 0.018*
Stomatitis 6(19.4) - 1(2.6) - 0.039*
Hypothyroidism 5(16.1) - 3(7.7) - 0.452
Blood bilirubin increased 5(16.1) 1(3.2) 3(7.7) 1(2.6) 0.452
Rash maculo-papular 4(12.9) - 4(10.3) - 1.000
  1. aPalmar-plantar erythrodysesthesia syndrome (NCI-CTCAE).
  2. *P < 0.05.
  3. **P < 0.01.